Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is a leading player in the fast-growing value-based care market, and its unique risk appetite in the underpenetrated specialty care market makes it well-positioned for growth. The company has strong barriers to entry due to its proprietary technology and partnerships with large health plans. With a diverse range of solutions and the ability to cross-sell and upsell to its large customers, as well as add new contracts, Evolent has an attractive growth proposition. Early indications show strong top-line growth expectations for 2026, leading to a potential normalized margin of 7-10% in 2027 and beyond, presenting significant upside for investors. Additionally, the company has a solid balance sheet and potential cash generation to help manage any potential leverage challenges. Despite a more conservative posture towards reserves, the company is set up for outsized growth in the coming years, which suggests a positive outlook for investors.

Bears say

Evolent Health is facing challenges with their specialty care management services, leading to a decline in revenue and a 5% underperformance in their 2026 results. The company's recent shift to a more conservative posture under their new CFO may provide more consistency in earnings, but their current financial outlook justifies a negative market outlook. With a decline in revenue and adjusted EBITDA estimates and a 10x EV/EBITDA multiple for their 2027 EBITDA estimate, our updated price target for Evolent Health is $6 per share.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.